OBJECTIVE: The paradigm that creatinaemia at birth is equal to maternal creatinaemia may also depend upon the quantification technique applied. Paired maternal-neonatal creatinaemia samples in whom Jaffe in both or compensated Jaffe (maternal) and enzymatic quantification (neonate) were applied. METHODS: Extreme low birth weight infants in two time intervals were included when paired maternal-neonatal creatinaemia samples were available. In cohort 1 (2000-2005), creatinaemia (mothers and neonates) was based on Jaffe assay. In cohort 2 (2007-2010), maternal creatinaemia was based on compensated Jaffe. In neonates, an enzymatic technique was applied. Unpaired Mann Whitney U, paired Wilcoxon and Bland-Altman were used. RESULTS: Based on 80 and 52 paired creatinaemia samples, there was no significant difference between maternal (0.80, 0.41-1.6 mg.dl(-1)) and neonatal creatinaemia (0.78, 0.31-1.46 mg.dl(-1)) in cohort 1 while a significant difference (p < 0.001) between maternal (0.6, 0.29-2.24 mg.dl(-1)) and neonatal creatinaemia (0.67, 0.4-2.2 mg.dl(-1)) was observed for cohort 2. Using Bland-Altman, the fit was perfect for cohort 1 (mean diff -0.02 mg.dl(-1)), but not for cohort 2 (-0.08 mg.dl(-1)). CONCLUSIONS: The quantification method affects the paradigm that creatinaemia at birth is similar to maternal creatinaemia. Maternal and neonatal creatinaemia values depend on the method used. Consequently, method-specific reference values are needed.
OBJECTIVE: The paradigm that creatinaemia at birth is equal to maternal creatinaemia may also depend upon the quantification technique applied. Paired maternal-neonatal creatinaemia samples in whom Jaffe in both or compensated Jaffe (maternal) and enzymatic quantification (neonate) were applied. METHODS: Extreme low birth weight infants in two time intervals were included when paired maternal-neonatal creatinaemia samples were available. In cohort 1 (2000-2005), creatinaemia (mothers and neonates) was based on Jaffe assay. In cohort 2 (2007-2010), maternal creatinaemia was based on compensated Jaffe. In neonates, an enzymatic technique was applied. Unpaired Mann Whitney U, paired Wilcoxon and Bland-Altman were used. RESULTS: Based on 80 and 52 paired creatinaemia samples, there was no significant difference between maternal (0.80, 0.41-1.6 mg.dl(-1)) and neonatal creatinaemia (0.78, 0.31-1.46 mg.dl(-1)) in cohort 1 while a significant difference (p < 0.001) between maternal (0.6, 0.29-2.24 mg.dl(-1)) and neonatal creatinaemia (0.67, 0.4-2.2 mg.dl(-1)) was observed for cohort 2. Using Bland-Altman, the fit was perfect for cohort 1 (mean diff -0.02 mg.dl(-1)), but not for cohort 2 (-0.08 mg.dl(-1)). CONCLUSIONS: The quantification method affects the paradigm that creatinaemia at birth is similar to maternal creatinaemia. Maternal and neonatal creatinaemia values depend on the method used. Consequently, method-specific reference values are needed.
Authors: Wei Zhao; Florentia Kaguelidou; Valérie Biran; Daolun Zhang; Karel Allegaert; Edmund V Capparelli; Nick Holford; Toshimi Kimura; Yoke-Lin Lo; José-Esteban Peris; Alison Thomson; John N van den Anker; May Fakhoury; Evelyne Jacqz-Aigrain Journal: Br J Clin Pharmacol Date: 2013-04 Impact factor: 4.335
Authors: Roosmarijn F W De Cock; Karel Allegaert; Janneke M Brussee; Catherine M T Sherwin; Hussain Mulla; Matthijs de Hoog; Johannes N van den Anker; Meindert Danhof; Catherijne A J Knibbe Journal: Pharm Res Date: 2014-05-02 Impact factor: 4.200
Authors: Yunjiao Wu; Karel Allegaert; Robert B Flint; Sinno H P Simons; Elke H J Krekels; Catherijne A J Knibbe; Swantje Völler Journal: AAPS J Date: 2022-02-25 Impact factor: 4.009